May 05, 2025 8:00am EDT iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
Apr 22, 2025 8:00am EDT iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
Apr 07, 2025 7:00am EDT iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
Jan 07, 2025 7:00am EST iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
Jan 02, 2025 7:00am EST iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
